Entrevistas

Dr. Andrew Hill: “The first-line use of TDF/3TC/DTG leads to lower risks of clinical obesity than combinations like TAF/FTC/DTG or TAF/FTC/BIC, or dual therapies like DTG/3TC”

Dr. Andrew Hill, MD, is a senior visiting Research Fellow in the Pharmacology Department at Liverpool University. His main research is on antiretroviral treatment for developing countries.  He is an advisor to the Clinton Foundation and the Bill and Melinda Gates Foundation, designing clinical trial programs of dose optimization for antiretrovirals. Dr. Hill is graduated from Oxford [...]

Dr. Andrew Hill: “The first-line use of TDF/3TC/DTG leads to lower risks of clinical obesity than combinations like TAF/FTC/DTG or TAF/FTC/BIC, or dual therapies like DTG/3TC”2023-11-28T09:26:03+01:00

Dr. Nicolas Huot: “Predicting the exact timeline for the widespread implementation of therapies involving the reprogramming of Natural Killer cells for HIV prevention and treatment is challenging”

Nicolas Huot is a postdoc fellow in Dr. M.Müller-Trutwin Lab at the pasteur institut in PARIS , studying the role of NK cells in secondary lymphoid tissues during SIV infection in natural hosts. He obtained my Ph.D. at university of Paris 12 in the Laboratory of Molecular and Structural Virology of Dr. Yves Gaudin studying [...]

Dr. Nicolas Huot: “Predicting the exact timeline for the widespread implementation of therapies involving the reprogramming of Natural Killer cells for HIV prevention and treatment is challenging”2023-11-28T09:36:24+01:00

Vicente Planelles: “Research in the field of senotherapeutics is still in its early stages, but initial results in the area of aging are highly encouraging”

Vicente Planelles, PhD, is a Professor in the Department of Pathology at the University of Utah and a member of the Cell Response and Regulation Program at Huntsman Cancer Institute. A major goal of his research is to understand, at a molecular level, the events that lead to apoptosis, the normal process of cell death. [...]

Vicente Planelles: “Research in the field of senotherapeutics is still in its early stages, but initial results in the area of aging are highly encouraging”2023-11-27T08:23:52+01:00

Dr. Jean Michel – Molina: “For biomedical prevention of HIV we have a number of drugs which are likely to be available in the future: long acting drugs for prevention”

Jean-Michel Molina is Professor of Infectious Diseases at the University of Paris Diderot - Paris 7, France, and Head of the Infectious Diseases Department at the Saint-Louis Hospital in Paris. Professor Molina’s primary clinical research interest lies in the area of the treatment of HIV infection, and he has been involved in a number of [...]

Dr. Jean Michel – Molina: “For biomedical prevention of HIV we have a number of drugs which are likely to be available in the future: long acting drugs for prevention”2023-11-27T08:23:21+01:00

Dra. Katharine Barr: “There are recent discoveries that support the development of new cure strategies”.

La Dra. Katharine Barr, quien participa en la sesión inaugural, nos habla sobre el reservorio del VIH y otras cuestiones relacionadas con los últimos avances y descubrimientos. Katharine Bar is an assistant professor at the University of Pennsylvania and an Infectious Diseases physician, clinical trialist and physician-scientist who studies the basic mechanisms and translational impact [...]

Dra. Katharine Barr: “There are recent discoveries that support the development of new cure strategies”.2023-11-26T16:29:07+01:00

Dr. Paul E. Sax: «We should continue to search for a cure as an aspirational goal”

El Dr. Paul Sax participa en la sesión inaugural del XIV Congreso de GeSIDA, con una ponencia titulada 'HAART, ART, 2DR, LA-ART.... What acronym is next?'. Nos adelanta su contenido en esta entrevista: Dr. Paul E. Sax is Clinical Director of the Division of Infectious Diseases at Brigham and Women's Hospital (BWH), where he holds [...]

Dr. Paul E. Sax: «We should continue to search for a cure as an aspirational goal”2023-11-25T11:34:56+01:00

Entrevista al Dr. Brad Jones, del Weill Cornell Medicine

El Dr. Brad Jones, del Weill Cornell Medicine de Nueva York, será el encargado de abrir la tercera jornada del XIII Congreso Nacional de GeSIDA con una interesante ponencia sobre resistencia a los linfocitos T citotóxicos en el reservorio del virus. Sobre ello nos habla a continuación: The resistance to CTL Killing in the HIV [...]

Entrevista al Dr. Brad Jones, del Weill Cornell Medicine2022-11-29T06:03:24+01:00

Entrevista a la Dra. Berta Rodés, del Instituto de Investigación Biomédica del Hospital Universitario La Paz (IdiPAZ)

La Dra. Berta Rodés, del IdiPAZ, será la encargada de cerrar la sesión plenaria de la tercera jornada del XIII Congreso Nacional de GeSIDA con la ponencia 'Biomarcadores epignéticos de envejecimiento en la infección por VIH', de la que nos avanza algunos aspectos relevantes en esta entrevista: En base a información que expondrá en el Congreso [...]

Entrevista a la Dra. Berta Rodés, del Instituto de Investigación Biomédica del Hospital Universitario La Paz (IdiPAZ)2022-11-29T05:55:52+01:00

Entrevista al Dr. Joel Palefsky, de la Universidad de California de San Francisco

El Dr. Joel Palefsky, de la Universidad de California de San Francisco, será uno de los ponentes de la sesión plenaria del lunes 28 de noviembre en el XIII Congreso Nacional GeSIDA, en la que profundizará en la prevención del cáncer anal. En esta entrevista nos avanza algunas claves de su intervención: What are the [...]

Entrevista al Dr. Joel Palefsky, de la Universidad de California de San Francisco2022-11-28T05:46:50+01:00

Entrevista al Dr. Steven Grinspoon, del Harvard Medical School

El Dr. Steven Grinspoon, del Harvard Medical School, será el encargado de ofrecer la primera ponencia inaugural del XIII Congreso Nacional de GeSIDA. Una esperada intervención en la que nos hablará sobre los avances y resultados preliminares que viene ofreciendo el estudio REPRIEVE. Your speech on REPRIEVE study will open the 2022 GeSIDA Congress. What are the main [...]

Entrevista al Dr. Steven Grinspoon, del Harvard Medical School2022-11-27T13:40:16+01:00
Ir a Arriba